This competitive intelligence report about Folate Receptor alpha (FRα) Targeted Therapies provides a competitor evaluation in the field of product candidates in research and development targeting Folate Receptor alpha (FRα). This report will be prepared on demand within one working day upon order placement. The report lists FRα -targeted R&D programs by R&D phase in a tabular format and describes in brief the profile of FRα-targeted therapies by drug modality.
Folate receptor alpha (FRα) is a cell surface GPI-anchored protein overexpressed in several solid tumors with highest prevalence in ovarian cancer and lung adenocarcinoma but restricted expression in normal tissues. An antibody drug conjugate (ADC) with a microtubule inhibitor (MTI) payload recently received accelerated approval from the FDA for FRα-expressing platinum-resistant ovarian cancer. Thus, folate receptor alpha is a clinically validated target with commercial potential as evidenced by sales of more than US$ 500 mln in its second full year of commercialization after first approval in 2022. Furthermore, the FRα-targeted ADC was the main reason for an equity value of US$ 10 bln when the originator company Immunogen was acquired by Abbvie.
Folate receptor alpha holds great promise as a target for next generation improved drug candidates based on drug modalities known to enhance effector function and/or to broaden the therapeutic window. Among FRα-targeted drug modalities in use for next generation therapy candidates are ADCs with novel targeting moieties and linker/payload technologies as well as novel small molecule drug conjugates. Furthermore, next generation cell therapy modalities and radiopharmaceuticals are advancing in the pipeline. And T-cell or NK cell engaging bispecific antibodies are further drug modalities applied to folate receptor alpha therapies.
Folate receptor alpha (FRα) is a cell surface GPI-anchored protein overexpressed in several solid tumors with highest prevalence in ovarian cancer and lung adenocarcinoma but restricted expression in normal tissues. An antibody drug conjugate (ADC) with a microtubule inhibitor (MTI) payload recently received accelerated approval from the FDA for FRα-expressing platinum-resistant ovarian cancer. Thus, folate receptor alpha is a clinically validated target with commercial potential as evidenced by sales of more than US$ 500 mln in its second full year of commercialization after first approval in 2022. Furthermore, the FRα-targeted ADC was the main reason for an equity value of US$ 10 bln when the originator company Immunogen was acquired by Abbvie.
Folate receptor alpha holds great promise as a target for next generation improved drug candidates based on drug modalities known to enhance effector function and/or to broaden the therapeutic window. Among FRα-targeted drug modalities in use for next generation therapy candidates are ADCs with novel targeting moieties and linker/payload technologies as well as novel small molecule drug conjugates. Furthermore, next generation cell therapy modalities and radiopharmaceuticals are advancing in the pipeline. And T-cell or NK cell engaging bispecific antibodies are further drug modalities applied to folate receptor alpha therapies.
